Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (D5W) Clear all
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

Ketorolac in Postoperative Infants: Pharmacokinetics and Safety

NCT01260883
View directory record Official record
Conditions
Postoperative Pain in Infants
Interventions
Ketorolac Tromethamine 1 mg/kg, Ketorolac Tromethamine 0.5 mg/kg, Placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Months to 18 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 4 Interventional

Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

NCT01174290
View directory record Official record
Conditions
Subsyndromal Delirium
Interventions
Haloperidol decanoate, Placebo
Drug
Lead sponsor
Northeastern University
Other
Eligibility
18 Years to 84 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 25, 2026, 7:17 AM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

NCT04863248
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
Interventions
Trilaciclib, Placebo, Docetaxel
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

NCT04294472
View directory record Official record
Conditions
BK Virus Infection
Interventions
MAU868, Placebo
Drug · Other
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

NCT03019653
View directory record Official record
Conditions
Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions
ANX-042, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 25, 2026, 7:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Erythromycin in GER-Associated Apnea of the Newborn

NCT01825473
View directory record Official record
Conditions
Gastroesophageal Reflux, Apnea, Bradycardia
Interventions
Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W)
Drug · Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Days and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Thiamine and Acute Decompensated Heart Failure: Pilot Study

NCT00680706
View directory record Official record
Conditions
Heart Failure, Diabetes
Interventions
Thiamine, Placebo
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

NCT02471690
View directory record Official record
Conditions
Healthy
Interventions
Oritavancin, Dextrose
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 25, 2026, 7:17 AM EDT
Terminated Phase 2 Interventional

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

NCT05517668
View directory record Official record
Conditions
Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions
Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
Drug
Lead sponsor
Richard Dart, MD, PhD
Other
Eligibility
10 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

NCT03102606
View directory record Official record
Conditions
Chemotherapy-induced Neutropenia
Interventions
Plinabulin, Pegfilgrastim, Saline Placebo, D5W Placebo
Drug · Other
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Stanford, California • Skokie, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 25, 2026, 7:17 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Study of Thyroid Hormones in Prematures

NCT02103998
View directory record Official record
Conditions
Transient Hypothyroxinemia of Prematurity (THOP)
Interventions
thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Hour to 24 Hours
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 3 Interventional

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

NCT04799249
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions
Trilaciclib, Placebo, Gemcitabine, Carboplatin
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Filgrastim in Alzheimer's Disease

NCT01617577
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
G-CSF; filgrastim, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
55 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

NCT01969409
View directory record Official record
Conditions
Ambulatory IPF
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Results available

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

NCT02112656
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
ThermoDox, Dummy infusion
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Milrinone in Congenital Diaphragmatic Hernia

NCT02951130
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions
Milrinone, Placebo (5% Dextrose)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
0 Hours to 168 Hours
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 25, 2026, 7:17 AM EDT
Recruiting Phase 3 Interventional

NAC vs Placebo on Opioid Use for Hysterectomy

NCT06039566
View directory record Official record
Conditions
Hysterectomy
Interventions
IV N-acetylcysteine, IV Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 25, 2026, 7:17 AM EDT
Terminated Phase 2 Interventional Results available

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

NCT01409031
View directory record Official record
Conditions
Persistent Pulmonary Hypertension, Respiratory Failure
Interventions
Intravenous Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 72 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 25, 2026, 7:17 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Ceftriaxone for Post-Treatment Lyme Disease

NCT06785402
View directory record Official record
Conditions
Post-Treatment Lyme Disease Syndrome
Interventions
Ceftriaxone treatment, Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

NCT02802228
View directory record Official record
Conditions
Portal Hypertension, Liver Cirrhosis
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 25, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

NCT01436500
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Ifetroban Injection, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 25, 2026, 7:17 AM EDT